Cat: IPD-X19788

Recombinant Human FLT3 Protein(HEK293), hFc

  • Price
  • Size
  • Number

    Order now. For delivery time, please consult customer service

  • Pre-sale guidance and worry-free after-sale service
  • Quality assurance for cold chain transportation

Analytical Data

  • Gene name

    FLT3

  • 简介

    FLT3 is a tyrosine-protein kinase receptor that regulates differentiation, proliferation, and survival of hematopoietic progenitor cells and dendritic cells. It phosphorylates downstream effectors such as SHC1 and AKT1, activating signaling cascades involving MTOR, RAS, and MAP kinases. FLT3 Protein, Human (HEK293, hFc) is the recombinant human-derived FLT3 protein, expressed by HEK293 , with C-hFc labeled tag.

  • Application

    SPRMSTBLIITCELISACELL ASSAYDRUG SCREENING

  • Biological Activity

    Measured by its binding ability in a functional ELISA. Immobilized human Flt-3 Ligand, at 1 μg/mL (100 μL/well) can bind Biotinylated Human FLT3 protein. The ED50 for this effect is 15.44 ng/mL. Measured by its binding ability in a functional ELISA. Immobilized human Flt-3 Ligand, at 1 μg/mL (100 μL/well) can bind Biotinylated Human FLT3 protein. The ED50 for this effect is 15.44 ng/mL.

  • Alternative Names

    CD135; FL cytokine receptor; FLK2; Flk-2; Flt-3; STK-1

  • Species

    Human

  • Source

    HEK293

  • Tag

    C-hFc

  • Purity

    Greater than 90% as determined by SDS-PAGE.

  • Uniprot

    P36888-1

  • Expression Region

    N27-S543

  • AA Sequence

    NQDLPVIKCVLINHKNNDSSVGKSSSYPMVSESPEDLGCALRPQSSGTVYEAAAVEVDVSASITLQVLVDAPGNISCLWVFKHSSLNCQPHFDLQNRGVVSMVILKMTETQAGEYLLFIQSEATNYTILFTVSIRNTLLYTLRRPYFRKMENQDALVCISESVPEPIVEWVLCDSQGESCKEESPAVVKKEEKVLHELFGTDIRCCARNELGRECTRLFTIDLNQTPQTTLPQLFLKVGEPLWIRCKAVHVNHGFGLTWELENKALEEGNYFEMSTYSTNRTMIRILFAFVSSVARNDTGYYTCSSSKHPSQSALVTIVEKGFINATNSSEDYEIDQYEEFCFSVRFKAYPQIRCTWTFSRKSFPCEQKGLDNGYSISKFCNHKHQPGEYIFHAENDDAQFTKMFTLNIRRKPQVLAEASASQASCFSDGYPLPSWTWKKCSDKSPNCTEEITEGVWNRKANRKVFGQWVSSSTLNMSEAIKGFLVKCCAYNSLGTSCETILLNSPGPFPFIQDNIS

  • Protein Length

    Extracellular Domain

  • Molecular Weight

    100-145 kDa

  • Endotoxin

    < 1.0 EU per μg protein as determined by the LAL method.

  • Form

    Freeze-dried powder

  • Buffer formulation

    PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.

  • Reconstitution

    Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.

  • Customization

    Site-directed mutagenesis Custom tag design Custom buffer formulation Custom full-length protein production

  • Stability Test

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.

  • Storage & Shelf Life

    Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.

  • Shipping

    In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.

Quality inspection process

Related Products

Protein Description

FLT3 (Fms-like tyrosine kinase 3) is a crucial receptor tyrosine kinase that plays a significant role in hematopoiesis and the development of various blood cells, particularly in the context of acute myeloid leukemia (AML). Mutations in the FLT3 gene, particularly the internal tandem duplication (ITD) and point mutations in the tyrosine kinase domain, are prevalent in a substantial subset of AML cases and are associated with poor prognosis. Given its vital role in cell proliferation and survival, FLT3 has emerged as a key therapeutic target in cancer treatment. Researchers have been focusing on developing FLT3 inhibitors to improve clinical outcomes for AML patients. The study of recombinant FLT3 proteins facilitates a deeper understanding of FLT3's structure, function, and the mechanisms by which mutations lead to leukemogenesis. Additionally, recombinant FLT3 proteins are instrumental in the design of targeted therapies, biomarker development, and in vitro assays that help evaluate the efficacy of potential FLT3 inhibitors. Overall, the ongoing research into FLT3 and its recombinant proteins not only enhances our understanding of AML pathology but also accelerates the development of innovative treatments aimed at targeting FLT3-driven malignancies.

E-mail

sales@ipodix.com

Sales

+1 2092920560


Contact us via WhatsApp

IPODIX Biotech Inc

2108 N ST, STE N
Sacramento, CA 95816, USA

For Product Information and Orders

sales@ipodix.com

For Business Collaboration

sales@ipodix.com

For CRO Services

sales@ipodix.com

For Technical Support

sales@ipodix.com
  • 50000+

    Recombinant Proteins

  • 100+

    Researchers

  • 100+

    Countries Served

  • ISO

    Certified Quality

Committed to Quality
Driven by Innovation

Learn More About US